Fitness costs for influenza b viruses carrying neuraminidase inhibitor-resistant substitutions: Underscoring the importance of e119a and h274y

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2718-2730

  Burnham, Andrew J ^a   Baranovich, Tatiana ^a   Marathe, Bindumadhav M ^a   Armstrong, Jianling ^a   Webster, Robert G ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME KINETICS; GENETIC STABILITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLUENZA B; INFLUENZA VIRUS B; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; ANTIVIRAL RESISTANCE; CELL CULTURE; CELL LINE; DOG; DRUG EFFECTS; ENZYMOLOGY; GENETICS; PROTEIN SECONDARY STRUCTURE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; INFLUENZA B VIRUS; NEURAMINIDASE; PROTEIN STRUCTURE, SECONDARY; VIRUS REPLICATION;

EID: 84898616627     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02628-13     Document Type: Article

References (78)

1. McCullers JA, Hayden FG. 2012. Fatal influenza B infections: time to reexamine influenza research priorities. J. Infect. Dis. 205:870-872. http://dx.doi.org/10.1093/infdis/jir865.
2. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, Emery SL, Drew CP, Shieh WJ, Uyeki TM, Zaki SR. 2012. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J. Infect. Dis. 205:895-905. http://dx.doi.org/10.1093/infdis/jir861.
3. CDC. 1 December 2013, accession date. FluView: influenza-Associated pediatric mortality. Centers for Disease Control and Prevention, Atlanta, GA. http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.
4. CDC. 1 December 2013, accession date. FluView: national and regional level outpatient illness and viral surveillance. Centers for Disease Control and Prevention, Atlanta, GA. http://gis.cdc.gov/grasp/fluview/fluportaldashboard. html.
5. FDA. 2013. Approved products: FluMist quadrivalent. U.S. Food and Drug Administration, Rockville,MD.http://www.fda.gov/BiologicsBlood Vaccines/Vaccines/ApprovedProducts/ucm293952.htm.
6. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. 2010. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28:2149-2156. http://dx.doi.org/10.1016/j. vaccine.2009.11.068.
7. Ambrose CS, Levin MJ. 2012. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 8:81-88. http://dx.doi.org/10.4161/hv.8.1. 17623.
8. Wathen MW, Barro M, Bright RA. 2013. Antivirals in seasonal and pandemic influenza-future perspectives. Influenza Other Respir. Viruses 7(Suppl 1):76-80. http://dx.doi.org/10.1111/irv.12049.
9. Farrukee R, Mosse J, Hurt AC. 2013. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev. Anti. Infect. Ther. 11:1135-1145. http://dx.doi.org/10.1586/14787210.2013.842466.
10. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ. 2012. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst. Rev. 1:CD008965. http://dx.doi.org/10.1002/14651858.CD008965.pub3.
11. Richard M, Ferraris O, Erny A, Barthelemy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B. 2011. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob. Agents Chemother. 55:2942-2952. http://dx.doi.org/10.1128/AAC.01699-10.
12. Baranovich T, Webster RG, Govorkova EA. 2011. Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr. Opin. Virol. 1:574-581. http://dx.doi.org/10.1016/j.coviro.2011.08.006.
13. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275. http://dx.doi.org/10.1126/science.1187816.
14. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44. http://dx.doi.org/10.1038/303041a0.
15. Nguyen HT, Fry AM, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17:159-173. http://dx.doi.org/10.3851/IMP2067.
16. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402. http://dx.doi.org/10.1128/AAC.01339-05.
17. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, Valette M, Lina B, Morfin F, Ferraris O. 2008. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41:25-28. http://dx.doi.org/10.1016/j.jcv.2007.10.019.
18. Hurt AC, Barr IG, Hartel G, Hampson AW. 2004. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62:37-45. http://dx.doi.org/10.1016/j.antiviral.2003.11.008.
19. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV. 2010. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2:2269-2289. http://dx.doi.org/10.3390/v2102269.
20. Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, Hayden FG. 2009. Surveillance for neuraminidase-inhibitorresistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 14:751-761. http://dx.doi.org/10. 3851/IMP1194.
21. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262. http://dx.doi.org/10.1086/ 314440.
22. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764. http://dx.doi.org/10.1086/500465.
23. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442. http://dx.doi.org/10.1001/jama.297.13.1435.
24. Burnham AJ, Baranovich T, Govorkova EA. 2013. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res. 100:520-534. http://dx.doi.org/10.1016/j.antiviral.2013.08.023.
25. Jackson D, Barclay W, Zurcher T. 2005. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55:162-169. http://dx.doi.org/10.1093/jac/dkh528.
26. Mishin VP, Hayden FG, Gubareva LV. 2005. Susceptibilities of antiviralresistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49:4515-4520. http://dx.doi.org/10.1128/AAC.49.11. 4515-4520.2005.
27. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
28. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. 2010. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res. 85:354-360. http://dx.doi.org/10.1016/j.antiviral.2009.10.022.
29. Ison MG, Hay A. 2013. Antivirals: targets and use, p 392-418. In Webster RG, Monto A, Braciale TJ, Lamb RA (ed), Textbook of influenza, 2nd ed. John Wiley & Sons, Ltd., Chichester, United Kingdom.
30. WHO. 2012. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87:369-374.
31. WHO. 2013. Meeting of the WHO expert working group on surveillance of influenza antiviral susceptibility, Geneva, July 2013. Wkly. Epidemiol. Rec. 88:477-482.
32. WHO. November 2012, posting date. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: neuraminidase inhibitor (NAI). World Health Organization, Geneva, Switzerland. www.who.int/influenza/ gisrs-laboratory/antiviral-susceptibility/nai-overview/en/index.html.
33. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425. http://dx.doi.org/10.1128/JVI.77.15.8418-8425.2003.
34. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG. 2008. Human-like receptor specificity does not affect the neuraminidaseinhibitor susceptibility of H5N1 influenza viruses. PLoS Pathog. 4:e1000043. http://dx.doi.org/10.1371/journal.ppat.1000043.
35. Thompson CI, Barclay WS, Zambon MC, Pickles RJ. 2006. Infection of human airway epithelium by human and avian strains of influenza a virus. J. Virol. 80:8060-8068. http://dx.doi.org/10.1128/JVI.00384-06.
36. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. 2002. Rescue of influenza B virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 99:11411-11416. http://dx.doi.org/10.1073/pnas.172393399.
37. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
38. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. 2010. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog. 6:e1000933. http://dx.doi.org/10.1371/journal.ppat.1000933.
39. McKimm-Breschkin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, Saito T, Tashiro M. 2013. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J. Antimicrob. Chemother. 68:2210-2221. http://dx.doi.org/10.1093/jac/dkt205.
40. Pearse AGE. 1980. Histochemistry, theoretical and applied, 4th ed, vol 3. Churchill Livingstone, New York, NY.
41. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D- N-Acetylneuraminate) substrate. Anal. Biochem. 94:287-296. http://dx.doi.org/10. 1016/0003-2697(79)90362-2.
42. Marathe BM, Leveque V, Klumpp K, Webster RG, Govorkova EA. 2013. Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. PLoS One 8:e71401. http://dx.doi.org/10.1371/journal.pone.0071401.
43. WHO. 2012. WHO information for molecular diagnosis of influenza virus in humans-update. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/gisrs-laboratory/molecular-diagnosis/en/.
44. Ilyushina NA, Bovin NV, Webster RG. 2012. Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium. J. Virol. 86:4724-4733. http://dx.doi.org/10.1128/JVI.06774-11.
45. Amaro RE, Swift RV, Votapka L, Li WW, Walker RC, Bush RM. 2011. Mechanism of 150-cavity formation in influenza neuraminidase. Nat. Commun. 2:388. http://dx.doi.org/10.1038/ncomms1390.
46. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71:3385-3390.
47. Wu Y, Qin G, Gao F, Liu Y, Vavricka CJ, Qi J, Jiang H, Yu K, Gao GF. 2013. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Sci. Rep. 3:1551. http://dx.doi.org/10. 1038/srep01551.
48. Couceiro JN, Paulson JC, Baum LG. 1993. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29:155-165. http://dx.doi.org/10.1016/0168-1702(93)90056-S.
49. Lieleg O, Lieleg C, Bloom J, Buck CB, Ribbeck K. 2012. Mucin biopolymers as broad-spectrum antiviral agents. Biomacromolecules 13:1724-1732. http://dx.doi.org/10.1021/bm3001292.
50. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78:12665-12667. http://dx.doi.org/10.1128/ JVI.78.22.12665-12667.2004.
51. Cohen M, Zhang XQ, Senaati HP, Chen HW, Varki NM, Schooley RT, Gagneux P. 2013. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol. J. 10:321. http://dx.doi.org/10.1186/1743-422X-10-321.
52. Colman PM, Hoyne PA, Lawrence MC. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67:2972-2980.
53. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:1834-1841. http://dx.doi.org/10.1128/AAC.01608-09.
54. Zurcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL. 2006. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J. Antimicrob. Chemother. 58:723-732. http://dx.doi.org/10. 1093/jac/dkl321.
55. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70:1818-1827.
56. Cheam AL, Barr IG, Hampson AW, Mosse J, Hurt AC. 2004. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res. 63:177-181. http://dx.doi.org/10.1016/j.antiviral.2004.04.004.
57. Barnett JM, Cadman A, Burrell FM, Madar SH, Lewis AP, Tisdale M, Bethell R. 1999. In vitro selection and characterisation of influenza B/Beijing/ 1/87 isolates with altered susceptibility to zanamivir. Virology 265: 286-295. http://dx.doi.org/10.1006/viro.1999.0058.
58. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG. 1995. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214:642-646. http://dx.doi.org/10. 1006/viro.1995.0078.
59. Wu NC, Young AP, Dandekar S, Wijersuriya H, Al-Mawsawi LQ, Wu TT, Sun R. 2013. Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J. Virol. 87:1193-1199. http://dx.doi.org/10.1128/JVI.01658-12.
60. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55:307-317. http://dx.doi.org/10.1016/S0166-3542(02)00053-0.
61. Rameix-Welti MA, Munier S, Le Gal S, Cuvelier F, Agou F, Enouf V, Naffakh N, van der Werf S. 2011. Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antivir. Ther. 16:597-603. http://dx.doi.org/10.3851/IMP1804.
62. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956. http://dx.doi.org/10.1056/NEJMp0900648.
63. Wang Q, Tian X, Chen X, Ma J. 2007. Structural basis for receptor specificity of influenza B virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 104:16874-16879. http://dx.doi.org/10.1073/pnas.0708363104.
64. Gambaryan AS, Robertson JS, Matrosovich MN. 1999. Effects of eggadaptation on the receptor-binding properties of human influenza A and B viruses. Virology 258:232-239. http://dx.doi.org/10.1006/viro.1999.9732.
65. Matrosovich MN, Gambaryan AS, Tuzikov AB, Byramova NE, Mochalova LV, Golbraikh AA, Shenderovich MD, Finne J, Bovin NV. 1993. Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology 196:111-121. http://dx.doi.org/10.1006/viro.1993.1459.
66. Baum EZ, Wagaman PC, Ly L, Turchi I, Le J, Bucher D, Bush K. 2003. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res. 59:13-22. http://dx.doi.org/10.1016/S0166- 3542(03)00011-1.
67. Hatakeyama S, Ozawa M, Kawaoka Y. 2011. In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Clin. Microbiol. Infect. 17:1332-1335. http://dx.doi.org/10.1111/j.1469-0691.2010.03313.x.
68. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084. http://dx.doi.org/10.1128/AAC.49.10.4075-4084.2005.
69. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111. http://dx.doi.org/10.1016/ S0166-3542(01)00214-5.
70. Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solorzano A, Garcia-Sastre A, Palese P, Bouvier NM. 2013. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat. Commun. 4:2854. http://dx.doi.org/10.1038/ ncomms3854.
71. Higgins RR, Beniprashad M, Chong-King E, Li Y, Bastien N, Low DE, Gubbay JB. 2012. Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient. J. Clin. Microbiol. 50:2500-2502. http://dx.doi.org/10.1128/JCM.00682-12.
72. Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA, Webster RG. 2011. Oseltamivir-resistant influenza A and B viruses pre-And postantiviral therapy in children and young adults with cancer. Pediatr. Infect. Dis. J. 30:284-288. http://dx.doi.org/10.1097/INF.0b013 e3181ff863b.
73. Kim YH, Kim HS, Cho SH, Seo SH. 2009. Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus. Viral Immunol. 22:423-430. http://dx.doi.org/10.1089/vim.2009.0045.
74. Bouvier NM, Lowen AC. 2010. Animal models for influenza virus patho-genesis and transmission. Viruses 2:1530-1563. http://dx.doi.org/10.3390/ v20801530.
75. Pica N, Chou YY, Bouvier NM, Palese P. 2012. Transmission of influenza B viruses in the guinea pig. J. Virol. 86:4279-4287. http://dx.doi.org/10.1128/ JVI.06645-11.
76. Wong DD, Choy KT, Chan RW, Sia SF, Chiu HP, Cheung PP, Chan MC, Peiris JS, Yen HL. 2012. Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. J. Virol. 86:10558-10570. http://dx.doi.org/10. 1128/JVI.00985-12.
77. Pozo F, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A. 2013. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J. Clin. Virol. 57:5-12. http://dx.doi.org/10.1016/j.jcv.2013.01.009.
78. International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group. 2012. Panel of influenza A and B viruses for assessment of neuraminidase inhibitor susceptibility. http://www.isirv.org/site/images/ stories/avg-documents/Resistance/avg%20leaflet%20nov12.pdf.